アルツハイマー病の新たな薬剤標的

Emerging Drug Targets in Alzheimer's Disease

発行	Decision Resources, Inc.
出版日	2007年12月	商品コード	58446
ページ情報	英文 31 Pages
価格	こちらの商品の販売は終了いたしました。

概要
原文目次
関連レポート

当商品の販売は、2011年12月21日を持ちまして終了しました。

原文目次

Abstract

The lack of effective treatments for Alzheimer's disease (AD) and an aging population create an enormous opportunity for disease-modifying drugs. Competition to develop new drugs for AD is in fact fierce, and the efficacy bar for current AD therapies is low; market penetration will therefore hinge on safety profiles. In that regard, the use of pharmacogenomics may cause AD patients to be turned away from certain therapies- but may also lead to better dosing and reduce the possibility of side effects and adverse drug interactions. Regardless: the soaring disease prevalence, the anticipated increase in early diagnosis and treatment, and the price premium a novel agent could command ensure that an approved AD disease-modifying drug will become a blockbuster.

Get the Answers You Need to Shape Your Strategy

The beta-amyloid peptide Aβ-42 (the main component of amyloid plaques in AD patients) is the AD target that has received the most attention from drug developers, and drugs targeting amyloid are the disease-modifying therapies furthest along in development. Which companies have promising, new drugs in development that target Aβ-42, and how do these companies' strategies and approaches differ?
Researchers are also interested in targeting neurofibrillary tangles (NFTs) to slow cognitive decline in AD patients. However, designing drugs that target NFTs has become more feasible only relatively recently, as good animal models have finally been created. Which companies are now developing drugs that target NFTs?
Genetic variations in drug-metabolizing enzymes can have a profound influence on the safety of a drug for any particular patient. Which allele in particular have researchers found affects the efficacy of current AD drugs?
Diabetes is a risk factor for AD, and the high level of insulin resistance seen in AD brains has led some researchers to call AD “type three diabetes.” What hypotheses have researchers set forth to explain the effect of impaired glucose regulation in AD? Which Big Pharma company already has an FDA-approved drug for diabetes that may find a lucrative new market in treating AD patients?
An immune-targeting vaccine against AD could become a blockbuster: as the first disease-modifying agent and the first biologic agent to launch in the AD market, such a drug could command a high price. Which companies are currently working on AD vaccines? How have newer versions of AD vaccines overcome serious side effects of earlier versions of active AD vaccines?

Scope

Pathophysiology: neuronal death, amyloid plaques, the Aβ-42 peptide, tau protein, neurofibrillary tangles, amyloid-derived diffusible ligands
Susceptibility factors: autosomal dominant gene mutations, allelic variation in apolipoprotein E, high cholesterol diets, diabetes
Pharmacogenomics: the influence of metabolizing enzymes on drug safety and efficacy; the influences of genetic variation on drug efficacy
Emerging drug targets: anti-Aβ-42 vaccine strategies, secretase inhibitors, γ-secretase modulators, anti-Aβ-42 fibrillization strategies, RAGE inhibitors, targeting beta amyloid, neurofibrillary tangles, GSK3-β inhibitors, cdk-5 modulators, targeting the tau protein, glucose metabolism, nerve growth factor, NMDA receptor, luteinizing hormone
Outlook for emerging AD targets: emergence of the first disease-modifying drugs; the prospects of Avandia, Flurizan, and bapineuzumab vaccines; polytherapy; prospects for earlier diagnosis; the upcoming burden on third-party payers; the role of pharmacogenomics

Mentioned in This Spectrum Report

Companies

Abbott Laboratories
AstraZeneca
Ceregene
CoMentis
Cytos
DeCode Genetics
Durect
Eisai
Elan
Eli Lilly
ExonHit Therapeutics
Forest Laboratories
GE Healthcare
Genentechv
Genizon BioSciences
GlaxoSmithKline
Grupo Grunenthal
Intellect Neurosciences
Kronos Science Laboratories
Lundbeck
Martek Biosciences
Medivation
Merck
Merz
Mitsubishi
Myriad Genetics
Neurochem
Neuropharma
Novartis
Perlegen Sciences
Pfizer
Prana Biotechnology
Roche
Sanofi -Aventis
Siemens
Takeda Pharmaceutical
TorreyPines Therapeutics
Toyoma Chemical
Transition Therapeutics
Translational Genomics
Research Institute (Tgen)
TransTech Pharma
Voyager Pharmaceutical
Wyeth

Targets

β secretase
γ secretase
Amyloid-derived diffusible ligands (ADDLs)
Amyloid fi brils
Amyloid plaques
Amyloid precursor protein (APP)
Aβ-42
beta amyloid aggregation
cdk-5
Cholesterol regulation
Glucose regulation
GSK3-β
HMG-CoA reductase
Immune system (via active and passive vaccines)
Luteinizing hormone
Metal ions
Mitochondrial dysfunction
Nerve growth factor
Neurofi brillary tangles (NFTs)
Neuron death
Neurotransmitter dysfunction
N-methyl-D-aspartate (NMDA) receptor
p25
Presenilin 1
Presenilin 2
Receptors for advanced glycation endproducts (RAGE)
Tau protein

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
The Pathophysiology of Alzheimer's Disease
Susceptibility Factors in AD
- Apolipoprotein E
- The ApoE ε4 Allele and Other AD Risk Factors
The Pharmacogenomics of AD
- The Influence of Metabolizing Enzymes on Drug Safety and Efficacy in Alzheimer's Disease
- The Influence of Genetic Variation on Drug Efficacy in Alzheimer's Disease
Emerging Drug Targets in AD
- Amyloid Plaques
  - Anti-Aβ-42 Vaccine Strategies
  - Secretase Inhibitors
  - γ-Secretase Modulators
  - Anti-Aβ-42 Fibrillization Strategies
  - RAGE Inhibitors
  - Targeting Beta Amyloid
- Neurofibrillary Tangles
  - GSK3-β Inhibitors
  - Cdk-5 Modulators
  - Targeting the Tau Protein
- Glucose Metabolism
- Other Targets
  - NMDA Receptor
  - Luteinizing Hormone
  - Nerve Growth Factor
Outlook for Emerging AD Targets
Bibliography